RIGEL PHARMACEUTICALS, INC. Intangible Assets, Net (Including Goodwill)
RIGEL PHARMACEUTICALS, INC. (RIGL) had Intangible Assets, Net (Including Goodwill) of $93.88 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Goodwill and Other
us-gaap:IntangibleAssetsNetIncludingGoodwill · last filed 2026-08-04
- 2026-06-30: Intangible Assets, Net (Including Goodwill) $93.88M.
- 2026-03-31: Intangible Assets, Net (Including Goodwill) $24.16M.
- 2025-12-31: Intangible Assets, Net (Including Goodwill) $24.75M.
- 2025-09-30: Intangible Assets, Net (Including Goodwill) $25.34M.
| Period end | Intangible Assets, Net (Including Goodwill) |
|---|---|
| 2026-06-30 | $93.88M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $24.16M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $24.75M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $25.34M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $25.92M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $26.51M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $27.10M 10-K · filed 2026-03-03 |
| 2024-09-30 | $27.69M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $28.27M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $28.86M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $13.88M 10-K · filed 2025-03-04 |
| 2023-09-30 | $14.15M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $14.41M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $14.68M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $14.95M 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |